Sarah Sinclair
A5103184375- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Pharmacy and Medical Practices
- Reflective Practices in Education
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
- Higher Education Learning Practices
- Innovations in Medical Education
- Pharmaceutical Practices and Patient Outcomes
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
Eastern Maine Medical Center
2024
PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results cohort biliary tract (BTC) ERBB2/3 amplification, overexpression, or mutation treated pertuzumab plus trastuzumab are reported. METHODS Eligible had BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2,...
Importance Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM DCIS are lacking. Objective To compare PROs at baseline over time patients randomized receive either GCC. Design, Setting, Participants This prespecified secondary outcome analysis used prospectively collected...
e13847 Background: Phenotypic frailty is a clear risk factor for higher morbidity and mortality in older breast cancer patients. How social factors may be potentially protective against phenotypic this population remains unclear. We sought to define these associations at baseline the Elevate cohort. Methods: The Longitudinal Cohort study prospectively enrolled patients >70 years with new invasive non-metastatic diagnosis between 4/19/19-9/28/23 from 7 US centers, participate 5 of clinical...
546 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort BTC ERBB2/3 amp, oe, or mut treated P+T are reported. Methods: Eligible had BTC, no standard treatment (tx) options, measurable disease, ECOG Performance Status (PS) 0-2, and adequate organ function. Genomic testing was done CLIA-certified, CAP-accredited labs. Dosing P 840 mg IV over 60 minutes (m), then 420...
PURPOSE The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) administration, as opposed to intravenous (IV), may reduce this commitment. This study sought estimate the difference in burden between IV and SC trastuzumab pertuzumab (HP). METHODS We prospectively enrolled a subcohort patients participating ADEPT trial (ClinicalTrials.gov identifier: NCT04569747 , investigating adjuvant HP plus endocrine therapy...